TABLE 2

Influence of intravenous GLP-1 (1.2 pmol · kg–1 · min–1) on mean concentrations of GLP-1, plasma glucose, insulin, C-peptide, and glucagon in patients with type 2 diabetes, subjects with IGT, and healthy control subjects (placebo conditions only)

Parameter (unit)Patients with type 2 diabetes
Subjects with IGT
Healthy control subjects (placebo)P*
Placebo conditionsGLP-1 conditionsPlacebo conditionsGLP-1 conditions
GLP-1 (pmol/l)12 ± 689 ± 124 ± 191 ± 207 ± 10.31
Glucose (mg/dl)179 ± 27113 ± 1188 ± 382 ± 389 ± 30.0005
Insulin (pmol/l)55 ± 1270 ± 1352 ± 1071 ± 1846 ± 50.82
C-peptide (nmol/l)0.76 ± 0.121.04 ± 0.150.75 ± 0.100.90 ± 0.180.62 ± 0.070.56
Glucagon (pmol/l)11 ± 210 ± 28 ± 28 ± 28 ± 20.24
  • Data are means ± SE. Average values of blood samples were drawn at 0, 15, 30, 45, and 60 min (GLP-1 and glucagon) or every minute (glucose, insulin, and C-peptide) of the 60-min sampling period.

  • *

    * Comparison of placebo experiments only; determined by analysis of variance

  • significant difference between placebo and GLP-1 treatment in one patient group (P < 0.05, t test).